NewLink Genetics Corporation Supports 2015 World Pancreatic Cancer Day
November 10, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Corporation Announces Promising Clinical Data on Indoximod at the Society for Neuro-Oncology Annual Meeting
November 09, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 09, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2015 Financial Results
November 03, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 03, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics to Participate in Three Upcoming Investor Conferences
October 30, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 30, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics to Host Its Third Quarter 2015 Earnings Conference Call on November 3, 2015
October 23, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 23, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease...
New Study Published in Cell Reports Highlights Indoximod, Demonstrates the Key Role of IDO in Both Local and Systemic Immunosuppression
October 13, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Awarded $18 Million Contract Option from BARDA
October 01, 2015 07:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Oct. 01, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United...
NewLink Genetics Corporation Announces Promising Clinical Data at European Cancer Congress 2015 (ECC)
September 27, 2015 10:45 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Sept. 27, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Announces Promising Phase 1b Data From the Combination of Indoximod and Ipilimumab in Melanoma at European Cancer Congress 2015 (ECC)
September 26, 2015 10:45 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Sept. 26, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Receives $8.1 Million Award From DTRA to Advance Ebola Vaccine
September 24, 2015 16:00 ET
|
Lumos Pharma, Inc.
AMES, Iowa, Sept. 24, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the Defense Threat Reduction Agency (DTRA) of the United States Department of Defense...